PSNL
Personalis, Inc. Common StockstockNASDAQ
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 15.86 | 2026-11-12 | -7.41% | 3.625 |
| 1M | 15.88 | 2026-10-19 | -7.53% | 0.580 |
| 3M | 15.81 | 2026-08-19 | -7.12% | 0.443 |
| 6M | 7.04 | 2026-05-19 | +108.59% | 1.472 |
| 1Y | 8.24 | 2025-11-19 | +78.22% | 2.206 |
| 2Y | 3.69 | 2024-11-19 | +297.97% | — |
| 5Y | 14.95 | 2021-11-19 | -1.77% | 2.204 |
Personalis, Inc. Common Stock (NASDAQ:PSNL) stock price today is $14.69, and today's volume is 2,132,263. PSNL is down 1.969% today. The 30 day average volume is 2.42M. PSNL market cap is $1.59B with 108.40M shares outstanding.